INVITED SPEAKER /MODERATOR INDEX Watts, Nelson B, MD Controversies in Osteoporosis and Low Bone Mass: Who Do We Treat, For How Long, and at What Risks? . . . . . . . . . . . . . . . . . .103 Disclosure: Amgen, 2, 5, 9; Baxter Healthcare, 5; Eli-Lilly, 2; InteKrin, 5; Johnson & Johnson, 5; MannKind, 5; MedPace, 5; Merck, 2; Novartis, 9; NPS, 2, 5; Pfizer, 5; Proctor & Gamble, 5, 9; san<strong>of</strong>i-aventis, 5, 9; Takeda Pharmaceuticals, 5; Warner Chilcott, 5, 9 Weaver, Cynthia A, MD Recovery Audit Contractor vs. Comprehensive Error Rate Testing Audits – Do You Know the Difference?. . . . . . . . . . . . . . . . . . . 66 Disclosure: Nothing to Disclose Wedderburn, Lucy R, MD, PhD Autologous Stem Cell Transplantation in Pediatric <strong>Rheumatology</strong>: Indications and Associated Morbidity . . . . . . . . . . . . . 68 Disclosure: Nothing to Disclose Weinblatt, Michael E, MD Methotrexate 2010 . . . . . . . . . . . . . . 55 Disclosure: cypress, 5 Weisman, Michael H, MD Year in Review . . . . . . . . . . . . . . . . . 27 Disclosure: Nothing to Disclose Epidemiology <strong>of</strong> Axial Spondyloarthritis. . . 88 Disclosure: Nothing to Disclose Weissmann, Gerald, MD An Infectious Etiology <strong>of</strong> Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . 26 Disclosure: Nothing to Disclose Weitz, Howard H, MD Perioperative Management <strong>of</strong> Selected Problems in Patients with Rheumatic Disease . . . . . . . . . . . . . . . . . . . . . . . . . .122 Disclosure: Nothing to Disclose Wener, Mark H, MD Labs and Treatment Options: What Do They Mean and How Do You Use? . . . . . . . . 131 Disclosure: BioRad Laboratories, 9 RC - <strong>Rheumatology</strong> Laboratory Testing: How it is Done and Why We Need to Know . . . . . . 24 Disclosure: BioRad Laboratories, 9 Wiener, Aimee, ARNP C, MSN Hand X-ray Review and Interpretation. . . . 58 Disclosure: Nothing to Disclose Wigley, Fredrick M, MD Systemic Sclerosis: New Therapeutic Approaches . . . . . . . . . . . . . . . . . .122 Disclosure: Actelion Pharmaceutical, 9; Bristol Myers-Squibb, 5; Novartis, 5; United Therapeutics, 9 Williams, David A, PhD Disparities and Pain: Examining Research, Practice and Policy . . . . . . . . . . . . . . 95 Disclosure: Nothing to Disclose Williams, John, PhD News from the National Institutes <strong>of</strong> Health: Updates and Opportunities. . . . . . . . . . 56 Disclosure: Nothing to Disclose Winthrop, Kevin L, MD, MPH Iatrogenic Misadventures: Complex Cases . . . . . . . . . . . . . . . . . . . . . . 85 Disclosure: Genentech, 5; Oxford Immunotech, 2; Wyeth, 5 Practice Potpourri . . . . . . . . . . . . . . . 86 Disclosure: Genentech, 5; Oxford Immunotech, 2; Wyeth, 5 Wolpaw, Terry M, MD, MHPE ACR REF Clinician Scholar Educator Lecture . . . . . . . . . . . . . . . . . . . . . 53 Disclosure: Nothing to Disclose Clinical Teaching Strategies in the Outpatient Clinic Setting . . . . . . . . . . . . . . . . . . 66 Disclosure: Nothing to Disclose Wright, Mary, BS, OT Musculoskeletal Pain and Cognitive Issues Related to Returning Military Personnel . . 75 Disclosure: Nothing to Disclose Rehabilitation in the Age <strong>of</strong> Biologics . . . . 54 Disclosure: Nothing to Disclose Wulffraat, Nico M, MD Autologous Stem Cell Transplantation in Pediatric <strong>Rheumatology</strong>: Indications and Associated Morbidity . . . . . . . . . . . . . 68 Disclosure: Nothing to Disclose X Ximenes, Antonio C, PhD ILAR Global Health Project . . . . . . . . . . 84 Disclosure: Nothing to Disclose Y Yazici, Hasan, MD Behcet’s Disease. . . . . . . . . . . . . . . . 28 Disclosure: Nothing to Disclose ACR/EULAR Academic Exchange Program . . . . . . . . . . . . . . . . . . . . 86 Disclosure: Nothing to Disclose Clinical Research Methodology . . . . . . .108 Disclosure: Nothing to Disclose Yazici, Yusuf, MD Clinical Research Methodology . . . . . . .107 Disclosure: BMS, Celgene, Centocor, Genentech, Roche, UCB, 5; BMS, Genentech, 8; Centocor, 2 York, Michael R, MD Scleroderma: Systemic Sclerosis . . . . . . 106 Disclosure: Nothing to Disclose Yung, Raymond L, MD Geriatric <strong>Rheumatology</strong> . . . . . . . . . . . 89 Disclosure: Nothing to Disclose News from the National Institutes <strong>of</strong> Health: Updates and Opportunities . . . . . . . . . 56 Disclosure: National Institute <strong>of</strong> Health, 2 Z Zibit, Melanie, MEd, MBA Web-based Support <strong>of</strong> Clinical Practice and Teaching: Twittering, Blogging, and Doing the Wiki. . . . . . . . . . . . . . . . . . . . . . .120 Disclosure: Nothing to Disclose 314 2010 Program Book
A Aarden, L 1825 Aarrass, S 1519, 1534 Abaci, N 2217 Abad, MA 516 Abbott, C 1141 Abdollahi-Roodsaz, S 713, 1535, 1730, 2230 Abdou, NI 462 Abdul Nasser, O 816 Abdulahad, D 1195 Abdulahad, W 1892, 2023 Abe, Y 1731 Abeles, AM 1845 Abeles, M 1845 Abellar, R 2231 Abignano, G 572, 671, 673 Ablin, JN 812 Aboushehde, K 1939 Abraham, D 674, 613, 1995, 2005 Abrahamowicz, M 72, 1036, 1056, 1555 Abrahamyan, L 1681 Abram, F 196, 938 Abramson, LS 234, 1673, 1691, 2017 Abramson, SB 137, 707, 708, 1390, 1477, 1490 Abreu, J 1529 Abril, A 777, 1637, 1652, 1654 Abud-Mendoza, C 416, 1146, 1166, 1407 Abufayyah, M 2152 Acar, H 1615 Acasuso, M 835 Accogli, A 265 Achan, P 1476 Achenbach, S 705, 959 Ackermann, F 2239 ACR/EULAR Commission To Redefine Remission in Rheumatoid Arthritis 2108 ACT-SURE Study Group 1840 Adachi, JD 969 Adam, P 2282 Adamec, J 1601 Adams, J 1540, 1552 Adams, MD 1673, 1691, 2017 Adebajo, AO 2082 Adhikari, T 1854, 1855 Adkins, D 1342 Adlerberth, I 1248 Adoue, D 2027 Adrianto, I 1579, 1585, 1586, 2144, 2147 Aegerter, P 1931 Affandi, A 1210 Afklint, E 394 Afridi, KS 2112 Afsarmanesh, N 998 Agarwal, S 602, 603, 612, 824, 1210, 1218, 1982, 2214 Agarwal, V 2086 Agashivala, N 2089 Ager, J 468 Aggarwal, R 563, 913, 925, 929, 930, 1147, 1175, 1193 Aghdassi, E 1156, 1165, 1178, 2120 Agrawal, H 853, 859 Agrawal, N 2205 Agrawal, S 856, 862 Agudo Bilbao, M 1650 Agüero-Balbin, J 1296 Aguilar -Valenzuela, R 1360 Aguilar-Salinas, C 459 Aguilar-Valenzuela, R 12, 1361 Aguilar-Valenzuela, RA 2253 Aguirre, D 953 Aguirre, MA 1357 Ah Kioon, M-D 1707 Ahearn, JM 620, 1399, 2106 Ahern, MJ 177 Ahl, J 105, 113 Åhlin, E 695, 1015 Ahluwalia, J 4 Ahmad, Y 769, 795, 1177 Ahmadi, N 1046, 1443, 2164, 2165, 2166 Ahmed, I 704, 910 Ahmed, K 777, 1637, 1654 Ahn, CW 1226 Ahn, IE 842, 1770 Ahn, JK 366, 372, 1297 Aigner, S 1125 Aikawa, N 224, 539, 1437 Aikawa, Y 280, 1467 Air, G 9, 24, 466 Airo, P 824, 829, 1987, 2214, 2226 Ajani, A 1052 Ajeganova, S 88 Ajmone Marsan, N 582 Akar, S 544, 666, 1282, 1283, 1921 Akazawa, S 2029 Akhavan, P 306, 336, 343, 1734, 1769 Akhlaghi, M 1289 Akhmetshina, A 607, 611, 614, 615, 616, 672 Akhtar, N 632, 633 Akhter, E 14, 487, 733, 2121 Akiba, H 1731 Akikusa, J 226, 248 Akin, C 307 Akiyama, C 434 Akkineni, R 992 Akkoc, N 544, 666, 1282, 1283, 1921 Akkoc, N 1970 Akkoc, Y 544 Aksentijevich, I 914, 1516, 2105 Aksu, K 822 Al Ghanim, N 1152 Al Mayouf, S 1305 Al Saleh, G 1413 Al Sarraf, N 816 Aláez, C 106 Alaka, K 175 Alarcón, G 445, 448, 476, 731, 1591, 1668, 1877, 2104, 2240, 2243 Alarcon, RT 356 Alarcón-Riquelme, ME 500, 1583, 1578, 1584, 1585, 1586, 1590, 1591, 1594, 1595, 2145, 2147, 2148, 2274 Alatorre, CI 52 Alaupovic, P 1030 Alavi, A 1105 Alawi, F 1907 Alba, MA 1314 Albath-Sadiki, A 2045 Albert, DA 992, 1537 Alberton, V 1173 Albert-Sabonnadiere, C 976 Albertsson, K 1392, 1393 Albesa, R 2250, 2251, 2252 Albom, MS 2233 Aldag, JC 49, 83 Al-Dhanhani, A 2120 Alegre, C 814 Alele, JD 960 Alessandri, E 578, 1236 Alessio, M 1439, 1685, 2033 Aletaha, D 73, 79, 296, 1013, 1745, 1795, 2256, 2258 Alevizos, I 1918, 2179 Alexander, C 1606 Alexander, K 464, 698 Alexanderson, H 2068 Alexopoulos, H 1895 Alfredsson, L 64, 645, 832, 1057, 1588, 2118, 2259 Ali, S 807 Aliabadi, P 198, 872 Alias, A 44 Aliprantis, AO 675, 1502 Alivernini, S 1069, 1239, 1604 Alizadeh, BZ 1599, 2214 All CATCH Investigators 306 Allaart, CF 295, 328, 334, 663, 1396, 1496, 1755, 1782 Allaire, SH 1349, 2143 Allam, Y 976 Allanore, Y 576, 580, 607, 616, 728, 729, 1810, 1991, 1994, 1987, 1988, 1992, 2000, 2226 Allen, D 1176 Allen, R 226, 248 Allgood, S 1192 Allievi, A 1173 Allison, J 1005 Allison, SJ 912 Alloza, I 896 Alm, GV 503 Almagor, O 2100 Almeida, C 1325 Almeida, GJM 2059, 2061 Almeida, JS 1403 Almodovar, R 986 Al-Mudhaffer, S 1306 Alonso-Ruiz, A 873 Alper, SL 1502 Alsalawy, A 798 Alsaleh, G 858 Alten, R 392, 770, 987, 1123, 1766, 1817, 1820, 2173 Alth<strong>of</strong>f, C 669, 2271 Altman, RD 187, 907 Altpeter, M 691, 2141 Alvarez, AA 1014 Alvarez-Carbonell, D 2231 Alvarez-Horine, S 97, 815 Alvarez-Leon, E 96 Alvarez-Rodriguez, L 1296 Álvaro-Gracia, J 1840 Alves, C 1775, 1776 Alves, JF 2043 Alyahya, R 1729 Amalini, C 717 Amano, H 1577 Amano, K 1793, 1823, 1839 Amarilyo, G 998 Ambarus, CA 2272 Ambler, N 1325 Amdur, RL 970 Amendola, A 176 Amengual, O 5, 10, 2254 Amezcua-Guerra, L 1614 Amin, MA 1417, 1504, 1721 Amin, S 15, 959 Amir, S 697 Amjadi, S 1058 Amos, C 2214, 2217 Amoura, Z 478, 915, 917, 1287, 1651, 1658, 1660, 1908, 1911, 2024, 2025, 2239 Ampel, NM 415 Anandarajah, A 849, 1051, 1369, 1620 Anania, C 1194 Ananyeva, LP 580 2010 Program Book 315 abstract author Index
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78:
2:45 PM 1405. Development of a Visi
- Page 79 and 80:
4:30 PM Anti-citrullinated Protein
- Page 81 and 82:
of Experimental Orthopedics, Univer
- Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92:
• compare the prevalence and epid
- Page 93 and 94:
6:45 PM Macrophage Activation Syndr
- Page 95 and 96:
Upon completion of this session, pa
- Page 97 and 98:
Session Overview: This roundtable d
- Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104:
• describe the role of IL-1 and I
- Page 105 and 106:
Session Overview: For the clinician
- Page 107 and 108:
• identify the aspects for day-to
- Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112:
Session Overview: Ultrasound and ma
- Page 113 and 114:
Session Overview: Fifty percent of
- Page 115 and 116:
1:20 PM Academic Rheumatology Seth
- Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
- Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
- Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
- Page 123 and 124:
Session Overview: We are witnessing
- Page 125 and 126:
Session Overview: Systemic sclerosi
- Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
- Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
- Page 131 and 132:
4:30 PM 2198. Association between V
- Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138:
• apply these basic statistics to
- Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
- Page 141 and 142:
Immunology, Oslo University Hospita
- Page 143 and 144:
9:15 AM 2239. Factors Associated wi
- Page 145 and 146:
Upon completion of this session, pa
- Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152:
ACR Poster Session A Cytokines, Med
- Page 153 and 154:
ACR Poster Session A 51. Associatio
- Page 155 and 156:
ACR Poster Session A 83. Respirator
- Page 157 and 158:
ACR Poster Session A 121. Bone Dens
- Page 159 and 160:
ACR Poster Session A 142. The Intra
- Page 161 and 162:
ACR Poster Session A 171. Early Pro
- Page 163 and 164:
ACR Poster Session A Pediatric Rheu
- Page 165 and 166:
ACR Poster Session A 233. Prevalenc
- Page 167 and 168:
ACR Poster Session A 266. Subtype S
- Page 169 and 170:
ACR Poster Session A 297. Body Weig
- Page 171 and 172:
ACR Poster Session A 325. Patient R
- Page 173 and 174:
ACR Poster Session A 356. Influence
- Page 175 and 176:
ACR Poster Session A 383. Efficacy
- Page 177 and 178:
ACR Poster Session A 409. Rituximab
- Page 179 and 180:
ACR Poster Session A 441. Recombina
- Page 181 and 182:
ACR Poster Session A 465. Immunoglo
- Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
- Page 187 and 188:
ACR Poster Session A 546. Prevalenc
- Page 189 and 190:
ACR Poster Session A 571. Epidemiol
- Page 191 and 192:
ACR Poster Session A 599. Validatio
- Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
- Page 195 and 196:
ACR Poster Session B 767. Economic
- Page 197 and 198:
ACR/ARHP Poster Session B 792. The
- Page 199 and 200:
ACR/ARHP Poster Session B Universit
- Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208:
ACR/ARHP Poster Session B 935. The
- Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212:
ACR Poster Session B 993. Early Exp
- Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
- Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222:
ACR Poster Session B hiroshima Memo
- Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
- Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
- Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
- Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
- Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
- Page 265 and 266: ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268: ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270: ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272: ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274: ACR/ARHP Poster Session C 1958. The
- Page 275 and 276: ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278: ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280: ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282: ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284: REF Industry Roundtable-supported S
- Page 285 and 286: REF Industry Roundtable-supported S
- Page 287 and 288: INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290: 2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292: 2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294: FLOOR PLANS 2010 Program Book 291
- Page 295 and 296: VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298: EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300: ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302: ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304: A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306: Cooper, Max D, MD Introduction . .
- Page 307 and 308: Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310: Physical Examination Skills for Imp
- Page 311 and 312: Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314: Rogers, Joan C, PhD, OTR/ L Underst
- Page 315: Terkeltaub, Robert, MD Crystallizin
- Page 319 and 320: Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322: Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
- Page 359 and 360: A α-galactosylceramide 505 A2A kno
- Page 361 and 362: Behcet’s syndrome 1284, 1288, 129
- Page 363 and 364: cost-utility 759, 1539 couples 1324
- Page 365 and 366: fibroblast like synoviocyte 27 fibr
- Page 367 and 368:
impact 1063, 1325 inactive disease
- Page 369 and 370:
methylation 826, 1253, 1489 methylt
- Page 371 and 372:
233, 234, 240, 243, 252, 262, 268,
- Page 373 and 374:
1599, 1600, 1603, 1605, 1606, 1609,
- Page 375 and 376:
1226, 1227, 1229, 1230, 1231, 1233,
- Page 377 and 378:
Abelson, Abby Goulder, MD Education
- Page 379 and 380:
Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382:
ACR Annual Meeting fellowS-in-train
- Page 383 and 384:
NOTES 2010 Program Book 381
- Page 385 and 386:
Enbrel ® (etanercept) Brief Summar
- Page 387 and 388:
Prescription Enbrel ® (etanercept)